Non-Hodgkin Lymphoma | Specialty

NCI Awards $1.4 Million Grant to Develop Test for B-Cell NHLs

October 14th 2014

Advanced Cell Diagnostics, Inc. (ACD) and Cleveland Clinic were jointly awarded a 2-year, $1.4 million grant from the National Cancer Institute (NCI) to develop and validate a diagnostic test to identify B-cell non-Hodgkin lymphomas (NHLs) from benign lymphoproliferative diseases.

Dr. Flinn Discusses the DYNAMO Trial

October 14th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Ibrutinib/Nivolumab Combination on Horizon in NHL

October 14th 2014

The combination of the investigational PD-1 immune checkpoint inhibitor nivolumab (Opdivo) and the oral BTK inhibitor ibrutinib (Imbruvica) will be evaluated in a phase I/II trial as a treatment for patients with non-Hodgkin lymphoma.

FDA Approves Bortezomib Regimen for Untreated MCL

October 9th 2014

The FDA has expanded the approval for bortezomib (Velcade) to include the frontline treatment of patients with mantle cell lymphoma.

FDA Grants Special Protocol Assessment to Phase III Ublituximab/Ibrutinib Study

September 21st 2014

TG Therapeutics has reached an agreement with the FDA regarding a Special Protocol Assessment for a phase III clinical trial exploring ublituximab in combination with ibrutinib for the treatment of patients with chronic lymphocytic leukemia.

Rosenberg Sees New Milestone in Latest CAR Findings

September 9th 2014

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

August 29th 2014

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

CAR T Cell Therapy Effective in Advanced B-cell Malignancies

August 26th 2014

Treatment with KTE-C19, a CD19-targeted CAR-modified T cell therapy, demonstrated an objective response rate of 92% in patients with advanced B-cell malignancies.

Lenalidomide Plus R-CHOP Effective in Aggressive DLBCL Subtype

August 19th 2014

The addition of lenalidomide to R-CHOP demonstrated promising efficacy in previously untreated patients with diffuse large B-cell lymphoma across all subtypes of the disease.

Ofatumumab Falls Short in DLBCL Trial

May 20th 2014

A phase III study exploring the chemotherapy regimen DHAP plus ofatumumab failed to meet its primary endpoint of prolongation in PFS when compared with DHAP plus rituximab for patients with relapsed or refractory DLBCL.

Dr. Seymour Discusses the Results of the PRIMA Study

April 28th 2014

John F. Seymour, MBBS, FRACP, PhD, from the Department of Hematology at the Peter MacCallum Cancer Centre in East Melbourne, Australia, discusses the results of the PRIMA study, which evaluated the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy in patients with advanced follicular lymphoma.

Dr. Melnick on Targeting EZH2 in DLBCL

April 10th 2014

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Dr. Melnick on Epigenetic Diversity in DLBCL

March 3rd 2014

Ari Melnick, MD, professor of medicine, Weill Cornell Medical College, discusses the association between epigenetic diversity and clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).

Changing Therapeutic Landscape in ALL, CLL, and NHL

January 22nd 2014

Combination Therapy in Large Cell Lymphomas

January 22nd 2014

Brentuximab Vedotin in Diffuse Large B-cell Lymphoma

January 22nd 2014

PI3K Inhibition in Hematologic Malignancies

January 22nd 2014

Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas

January 22nd 2014

Combining and Sequencing New Agents in CLL

January 22nd 2014

Efficacy and Future Role of Ibrutinib in CLL and MCL

January 22nd 2014